Mirvetuximab soravtansine + Carboplatin
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Ovarian Cancer
Conditions
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Trial Timeline
Sep 28, 2022 → Nov 1, 2026
NCT ID
NCT05456685About Mirvetuximab soravtansine + Carboplatin
Mirvetuximab soravtansine + Carboplatin is a phase 2 stage product being developed by AbbVie for High Grade Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05456685. Target conditions include High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer.
What happened to similar drugs?
3 of 20 similar drugs in High Grade Ovarian Cancer were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05456685 | Phase 2 | Active |
Competing Products
20 competing products in High Grade Ovarian Cancer